Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Noopur Raje, Garson David Roodman, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Evangelos Terpos, Lisa Kennedy, Lorenzo Sabatelli, Michele Intorcia & Guy Hechmati. (2018) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of Medical Economics 21:5, pages 525-536.
Read now
Read now
Feng Xie, Robert B. Hopkins, Natasha Burke, Mohdhar Habib, Carlo De Angelis, Mark Pasetka, Angie Giotis & Ron Goeree. (2014) Time and Labor Costs Associated With Administration of Intravenous Bisphosphonates for Breast or Prostate Cancer Patients With Metastatic Bone Disease: A Time and Motion Study. Hospital Practice 42:2, pages 38-45.
Read now
Read now
Louis S Matza, Ze Cong, Karen Chung, Alison Stopeck, Katia Tonkin, Janet Brown, Ada Braun, Kate Van Brunt & Kelly McDaniel. (2013) Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Preference and Adherence 7, pages 855-865.
Read now
Read now
Allan Lipton & Arun Balakumaran. (2012) Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. Expert Review of Clinical Pharmacology 5:4, pages 359-371.
Read now
Read now
Akshara Richhariya, Yi Qian, Yufan Zhao & Karen Chung. (2012) Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis. Cancer Management and Research 4, pages 55-60.
Read now
Read now
Articles from other publishers (8)
Philippe Moreau, Shaji Kumar, Ralph Boccia, Shinsuke Iida, Hartmut Goldschmidt, Kim Cocks, Andrew Trigg, Anita Zahlten-Kumeli, Emre Yucel, Sumeet S. Panjabi & Meletios Dimopoulos. (2019) Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study). Leukemia 33:12, pages 2934-2946.
Crossref
Crossref
Adem Sav, Asiyeh Salehi, Frances S. Mair & Sara S. McMillan. (2017) Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature. BMC Medical Research Methodology 17:1.
Crossref
Crossref
Jean-Jacques Body, Francesca Gatta, Erwin De Cock, Sunning Tao, Persefoni Kritikou, Pauline Wimberger, Jeroen Mebis, Marc Peeters, Paolo Pedrazzoli, Augusto Caraceni, Vincenzo Adamo & Guy Hechmati. (2017) An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. Supportive Care in Cancer 25:9, pages 2823-2832.
Crossref
Crossref
Maria Winzer, Martina Rauner & Lorenz C. Hofbauer. 2016. Principles of Osteoimmunology. Principles of Osteoimmunology
239
255
.
Thierry Lebret, Jean-Loup Mouysset, Alain Lortholary, Claude El Kouri, Laurent Bastit, Meryem Ktiouet, Khemaies Slimane, Xavier Murraciole & Stéphane Guérif. (2013) Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient–nurse satisfaction. Supportive Care in Cancer 21:6, pages 1613-1620.
Crossref
Crossref
Thierry Lebret, Jean-Loup Mouysset, Alain Lortholary, Claude El Kouri, Laurent Bastit, Meryem Ktiouet, Slimane Khemaies, Xavier Murraciole & Stéphane Guérif. (2013) Traitement à domicile par l’acide zolédronique chez des patients atteints de tumeurs solides : observance et satisfaction du patient et de l’infirmier. Bulletin du Cancer 100:3, pages 247-257.
Crossref
Crossref
David L. Lacey, William J. Boyle, W. Scott Simonet, Paul J. Kostenuik, William C. Dougall, John K. Sullivan, Javier San Martin & Roger Dansey. (2012) Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. Nature Reviews Drug Discovery 11:5, pages 401-419.
Crossref
Crossref
Alan Oglesby, Bintu Sherif, Dawn Odom, Michael Leahy & Yi Qian. (2009) Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncology 6:11, pages 494-502.
Crossref
Crossref